Based in Redwood City, California, Relypsa is dedicated to discovering and developing new polymeric drugs that are not absorbed by the body for the treatment of conditions in the cardiovascular and renal areas. Their lead product candidate, RLY5016, is a non-absorbed potassium binder designed to manage hyperkalemia. Relypsa aims to expand its product pipeline using its proprietary polymer platform, with a focus on addressing conditions that are overlooked and undertreated in the gastrointestinal tract.